INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced today that Anat Ashkenazi has resigned from her position as Chief Financial Officer (CFO) to explore a new career... ByInvesting.com ...

As Alphabet expands its AI efforts, the company expects to increase investments in capital expenditure (capex) for technical ...

One of the highlights of Eli Lilly's third-quarter results ... said Lilly's chief financial officer Anat Ashkenazi on the call. Now, Lilly's focus is on international expansion – with approvals ...

Eli Lilly has called on financial regulators to ... The issue was also alluded to by Lilly’s chief financial officer, Anat Ashkenazi, on the company’s fourth-quarter results call yesterday ...

The new CFO, Anat Ashkenazi, you might remember, she was at Eli Lilly, she tells a terrific story. We’ll be listening for anything about the growth of Google’s cloud infrastructure business.

Ashkenazi began her tenure as CFO on July 31, joining the tech giant from an impressive career as finance chief at drugmaker Eli Lilly. On her debut earnings call in Q3 last October, she stated ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Pharmaceutical company Eli Lilly (LLY) has been raking it in lately thanks to its two flagship products: Mounjaro and Zepbound. These two have ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.